CorMedix announced that the FDA has accepted the supplemental New Drug Application for REZZAYO (rezafungin) to be used as a preventive treatment for invasive fungal diseases, granting it Priority Review with a target decision date in Q1 2027. This application is supported by positive Phase III trial results from the ReSPECT study, which compared weekly REZZAYO to standard treatments in adults undergoing allogeneic hematopoietic stem cell transplants. If approved, CorMedix plans to start promoting REZZAYO for this new use in the second half of 2027. REZZAYO is already FDA-approved for treating candidemia and invasive candidiasis in patients with limited options, and this new indication could address significant unmet needs in fungal disease prevention.
CorMedix's FDA Priority Review announcement for REZZAYO provides context for health-sector trading activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Oct 19, 2026 18:01 WIB: out of 150 priced health-sector US stocks, 73 rose and 47 fell. Among notable movers, CTXR rose 4.13% to USD 0.48 with a typical hold time of 17 days, contrasting with HRTX at USD 0.37 gaining 2.49% and a longer hold time of 36 days, while RXRX traded at USD 3.55 up 2.45% with a 21-day hold time.
Bill Gross, a serial entrepreneur behind over 175 companies, has launched Idealab.ai, a platform using AI to generate and share over 1.2 million business ideas based on real-world problems. The platform aims to lower barriers to entrepreneurship by h...
The Portnoy Law Firm has launched an investigation into Cardinal Infrastructure Group for possible securities fraud following the company's Q2 2026 financial report. Cardinal revealed a decline in its gross profit margin to 10.8%, down from 13.9% the...
AIOS Tech Inc. announced an agreement to acquire SmartCore Holdings Limited in an all-stock transaction valued at approximately $100 million. The deal will issue 33.3 million AIOS shares to SmartCore's sellers, who will hold about 80% of AIOS shares ...
XBiotech announced positive results from the Phase II TASKIN trial, where their antibody vilamakitug combined with standard chemotherapy improved 12-month overall survival to 61.3% in refractory metastatic colorectal cancer patients, surpassing the s...
Proof and Circle Internet Group demonstrated a new system where AI agents can prove the identity of the person they represent using Proof's x401 open identity protocol and pay merchants in USDC via Circle's x402 payment protocol. This innovation addr...
